1–2 of 2 results for gene agnostic
One Year Follow-Up in a Phase ½ Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa
Benjamin Bakall, MD, PhD
Updates from the Field
2024
BVA Analysis of Low- or High-Dose MCO-010 Optogenetics Therapy for Retinitis Pigmentosa: First Time 100-Week TOPLINE Results From a Phase 2b/3 Clinical trial (RESTORE)
Michael A. Singer, MD